SCHEMBL1794892

SCHEMBL1794892

CCCC(NC1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(F)(F)F)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ PSEN1 P49768 20/20 1.00
▸ PSEN2 P49810 20/20 1.00
▸ APH1B Q8WW43 20/20 1.00
▸ NCSTN Q92542 20/20 1.00
▸ APH1A Q96BI3 20/20 1.00
▸ PSENEN Q9NZ42 20/20 1.00
▸ GSAP A4D1B5 1/20 0.90

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nirogacestat SCHEMBL13184912 0.95 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
Nirogacestat SCHEMBL19422226 0.95 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
Nirogacestat SCHEMBL29388600 0.95 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
Nirogacestat SCHEMBL13184754 0.95 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
Nirogacestat SCHEMBL1796299 0.95 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
Nirogacestat SCHEMBL26374374 0.95 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
Nirogacestat SCHEMBL26374369 0.95 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
Nirogacestat SCHEMBL29658278 0.95 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
Nirogacestat SCHEMBL21050500 0.95 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
Nirogacestat SCHEMBL31142148 0.94 PSEN1 (0.99) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730119-B1 IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PROD INC (US) 2008-06-25 — — EP claimed
US-7951958-B2 Imidazole compounds for the treatment of neurodegenerative disorders PFIZER INC. (US) 2011-05-31 — — US disclosed
Send feedback